133 related articles for article (PubMed ID: 28647317)
1. Associations of systemic sphingolipids with measures of hepatic function in liver cirrhosis are related to cholesterol.
Krautbauer S; Wiest R; Liebisch G; Buechler C
Prostaglandins Other Lipid Mediat; 2017 Jul; 131():25-32. PubMed ID: 28647317
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis.
Feder S; Wiest R; Weiss TS; Aslanidis C; Schacherer D; Krautbauer S; Liebisch G; Buechler C
Lipids Health Dis; 2021 Jan; 20(1):6. PubMed ID: 33461570
[TBL] [Abstract][Full Text] [Related]
3. Transjugular Intrahepatic Porto-Systemic Shunt in Patients with Liver Cirrhosis and Model for End-Stage Liver Disease ≥15.
Ascha M; Hanouneh M; S Ascha M; Zein NN; Sands M; Lopez R; Hanouneh IA
Dig Dis Sci; 2017 Feb; 62(2):534-542. PubMed ID: 27154510
[TBL] [Abstract][Full Text] [Related]
4. Connective tissue growth factor level is increased in patients with liver cirrhosis but is not associated with complications or extent of liver injury.
Bauer S; Eisinger K; Wiest R; Karrasch T; Scherer MN; Farkas S; Aslanidis C; Buechler C
Regul Pept; 2012 Nov; 179(1-3):10-4. PubMed ID: 22960408
[TBL] [Abstract][Full Text] [Related]
5. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
[TBL] [Abstract][Full Text] [Related]
6. Adipokines in Liver Cirrhosis.
Buechler C; Haberl EM; Rein-Fischboeck L; Aslanidis C
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28661458
[TBL] [Abstract][Full Text] [Related]
7. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt.
Trebicka J; Krag A; Gansweid S; Appenrodt B; Schiedermaier P; Sauerbruch T; Spengler U
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1218-25. PubMed ID: 21971377
[TBL] [Abstract][Full Text] [Related]
8. Different scoring systems in predicting survival in Chinese patients with liver cirrhosis undergoing transjugular intrahepatic portosystemic shunt.
Zhang F; Zhuge Y; Zou X; Zhang M; Peng C; Li Z; Wang T
Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):853-60. PubMed ID: 24915489
[TBL] [Abstract][Full Text] [Related]
9. Transjugular intrahepatic portosystemic shunt in cavernomatous portal vein occlusion.
Brountzos EN; Malagari K; Alexopoulou E; Nikolaou VE; Panagiotou I; Argyriou P; Efstathopoulos E; Kelekis DA
Hepatogastroenterology; 2004; 51(58):1168-71. PubMed ID: 15239270
[TBL] [Abstract][Full Text] [Related]
10. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites.
Ochs A; Rössle M; Haag K; Hauenstein KH; Deibert P; Siegerstetter V; Huonker M; Langer M; Blum HE
N Engl J Med; 1995 May; 332(18):1192-7. PubMed ID: 7700312
[TBL] [Abstract][Full Text] [Related]
11. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
Berres ML; Lehmann J; Jansen C; Görtzen J; Meyer C; Thomas D; Zimmermann HW; Kroy D; Schumacher F; Strassburg CP; Sauerbruch T; Trautwein C; Wasmuth HE; Trebicka J
Liver Int; 2016 Mar; 36(3):386-94. PubMed ID: 26212075
[TBL] [Abstract][Full Text] [Related]
12. Early Liver Failure after Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis with Model for End-Stage Liver Disease Score of 12 or Less: Incidence, Outcome, and Prognostic Factors.
Luca A; Miraglia R; Maruzzelli L; D'Amico M; Tuzzolino F
Radiology; 2016 Aug; 280(2):622-9. PubMed ID: 26982564
[TBL] [Abstract][Full Text] [Related]
13. The soluble mannose receptor is released from the liver in cirrhotic patients, but is not associated with bacterial translocation.
Laursen TL; Rødgaard-Hansen S; Møller HJ; Mortensen C; Karlsen S; Nielsen DT; Frevert S; Clemmesen JO; Møller S; Jensen JS; Bendtsen F; Grønbaek H
Liver Int; 2017 Apr; 37(4):569-575. PubMed ID: 27706896
[TBL] [Abstract][Full Text] [Related]
14. Circulating lipocalin 2 is neither related to liver steatosis in patients with non-alcoholic fatty liver disease nor to residual liver function in cirrhosis.
Meier EM; Pohl R; Rein-Fischboeck L; Schacherer D; Eisinger K; Wiest R; Krautbauer S; Buechler C
Cytokine; 2016 Sep; 85():45-50. PubMed ID: 27288631
[TBL] [Abstract][Full Text] [Related]
15. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
[TBL] [Abstract][Full Text] [Related]
16. Circulating Elastin Fragments Are Not Affected by Hepatic, Renal and Hemodynamic Changes, But Reflect Survival in Cirrhosis with TIPS.
Nielsen MJ; Lehmann J; Leeming DJ; Schierwagen R; Klein S; Jansen C; Strassburg CP; Bendtsen F; Møller S; Sauerbruch T; Karsdal MA; Krag A; Trebicka J
Dig Dis Sci; 2015 Nov; 60(11):3456-64. PubMed ID: 26138655
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and outcomes of transjugular intrahepatic portosystemic shunt recipients in the VA Healthcare System.
Lerrigo R; Beste LA; Leipertz SL; Green PK; Lok AS; Kogut MJ; Ioannou GN
Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):667-75. PubMed ID: 26886386
[TBL] [Abstract][Full Text] [Related]
18. Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites.
Wong W; Liu P; Blendis L; Wong F
Am J Med; 1999 Mar; 106(3):315-22. PubMed ID: 10190381
[TBL] [Abstract][Full Text] [Related]
19. Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites.
Alam I; Bass NM; Bacchetti P; Gee L; Rockey DC
Am J Gastroenterol; 2000 Jan; 95(1):199-203. PubMed ID: 10638583
[TBL] [Abstract][Full Text] [Related]
20. Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension.
Eisinger K; Krautbauer S; Wiest R; Karrasch T; Hader Y; Scherer MN; Farkas S; Aslanidis C; Buechler C
Eur J Clin Invest; 2013 Sep; 43(9):926-32. PubMed ID: 23855493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
